6446.TW PharmaEssentia

Healthcare Drug Manufacturers - Specialty & Generic Taiwan Stock Exchange
1,270 TWD
Close of Nov 7, 2026
452.06 1,645
Market cap
TWD 525B
P/E
73.1x
P/B
14.27x
ROE
22.3%
Dividend yield
0.07%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is 6446.TW undervalued?

Graham number

The Graham number of PharmaEssentia cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PharmaEssentia fundamental analysis

No fundamental analysis for PharmaEssentia yet.

PharmaEssentia stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; N…

Full company profile